Help us: Donate
Follow us on:
×

Tag: Insilico Medicine

October 16, 2020
Insilico Medicine has announced a historic deal with the Taisho Pharmaceutical Company, which is based in Japan, in a partnership to identify and develop new senolytic drugs. The companies have agreed to collaborate on AI-powered drug discovery focused on identifying molecules to remove problematic senescent cells. Cellular SenescenceAs your body ages, more of your cells...
April 22, 2020
In this 80-minute interview with Brent Nally, Dr. Alex Zhavoronkov of Insilico Medicine discusses the relationship between COVID-19 and age-related diseases, including how this 'gerophilic' disease primarily afflicts the elderly, how COVID-19 has affected research on aging, and many related topics, including how extending lifespan without extending healthspan puts our society at risk of hyperinflation...
December 05, 2019
A type of artificial intelligence technique is now being used to develop new drugs and therapies and could perhaps even help to solve aging. An urgent need for aging biomarkers There has long been an urgent need in our field to develop increasingly accurate biomarkers of aging so that the efficacy of interventions can be...
October 14, 2019
We're continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Dr. Qingsong Zhu, the COO of Insilico Medicine, discussed the use of deep learning in creating biomarkers for aging. Initially...
September 02, 2019
Insilico Medicine has achieved a world first by successfully designing, synthesizing, and validating a new drug from the ground up and taking just 46 days to do so. It achieved this impressive feat using AI. This is the first time that AI has been used to successfully create a new drug, and it took record...
June 13, 2018
We were interested to learn that Juvenescence Limited, a biotech and development company involved in the development of therapies that target the aging processes, has successfully raised $50 million in a series A financing round. Jim Mellon, the chairman of Juvenescence Limited, said, "We are delighted with the progress we have made and the faith...